<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251806</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00165595</org_study_id>
    <secondary_id>R01HL147261</secondary_id>
    <nct_id>NCT04251806</nct_id>
  </id_info>
  <brief_title>Sleep-disordered Breathing in Infants With Myelomeningocele</brief_title>
  <official_title>Sleep-disordered Breathing in Infants With Myelomeningocele</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether the risk for sleep-disordered breathing in infants with
      myelomeningocele (a severe form of spina bifida) differs among those who underwent fetal vs.
      postnatal surgery, and to examine the link between sleep-disordered breathing and
      neurodevelopment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myelomeningocele (MMC), the most severe form of spina bifida, is characterized by exposure of
      the spinal cord through a spinal defect. Sleep-disordered breathing (SDB) is common in
      children with MMC and is a risk factor for sudden death. Abnormal sleep physiology is likely
      multifactorial, related to MMC level, brainstem dysfunction, musculoskeletal factors, and
      pulmonary abnormalities. In infants, SDB may be treatable with oxygen, caffeine, or positive
      airway pressure. Yet, SDB screening is not routine, even in centers with specialized MMC
      programs.

      Evaluation of sleep in neonates who require intensive care is an emerging opportunity with
      potential for major impact on health and quality of life for affected children. As SDB and
      abnormal sleep are potentially treatable, early assessment and intervention could become an
      integral part of a multidisciplinary treatment strategy to optimize long-term medical and
      neurodevelopmental outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of neonatal sleep-disordered breathing (SDB) in infants who had fetal versus postnatal myelomeningocele repair.</measure>
    <time_frame>35-42 weeks postmenstrual age</time_frame>
    <description>Neonatal sleep studies will be used to capture neonatal Apnea-Hypopnea Index (AHI), the most widely accepted summary measure of sleep-disordered breathing severity for newborns who had fetal (prenatal) versus postnatal myelomeningocele repair.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association between neonatal sleep-disordered breathing and neurodevelopmental outcomes at 2 years of age for infants with myelomeningocele.</measure>
    <time_frame>22-26 months corrected age</time_frame>
    <description>Bayley-IV developmental exams will be performed on all subjects around 2-years of age. The Bayley-IV will determine if the subject's level of thinking, language, and motor skills are similar to the level of most children their age. Our assessment will be based off the Cognitive Subscale Score. It has a range from 40-160 with a mean score of 100 and standard deviation of 15. The scores will analyzed with regression models and general linear models to see if there is an association between Neonatal AHI for infants with myelomeningocele, fetal vs. postnatal myelomeningocele repairs, and neurodevelopmental outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of sleep-disordered breathing at 2-years of age</measure>
    <time_frame>22-26 months corrected age</time_frame>
    <description>Sleep studies will be performed at 2-years of age to capture AHI and compare to neonatal AHI for neonates who had fetal versus postnatal myelomeningocele repair.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">173</enrollment>
  <condition>Sleep-disordered Breathing</condition>
  <condition>Myelomeningocele</condition>
  <arm_group>
    <arm_group_label>Prenatal Repair</arm_group_label>
    <description>This group received prenatal myelomeningocele repair.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postnatal Repair</arm_group_label>
    <description>This group received postnatal myelomeningocele repair.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>neonatal polysomnography</intervention_name>
    <description>This procedure will allow the detection of sleep-disordered breathing in the neonatal period.</description>
    <arm_group_label>Postnatal Repair</arm_group_label>
    <arm_group_label>Prenatal Repair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>2-year Bayley Exam</intervention_name>
    <description>This procedure will evaluate neurodevelopmental outcomes.</description>
    <arm_group_label>Postnatal Repair</arm_group_label>
    <arm_group_label>Prenatal Repair</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>2-year polysomnography</intervention_name>
    <description>This procedure will allow the detection of sleep-disordered breathing at 2 years of age.</description>
    <arm_group_label>Postnatal Repair</arm_group_label>
    <arm_group_label>Prenatal Repair</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Myelomeningocele is characterized by exposure of the spinal cord through a spinal defect.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: neonates with myelomeningocele who are cared for at a study center NICU
        are eligible to participate after myelomeningocele repair.

        Exclusion Criteria:

          -  born at &lt;30 weeks gestation

          -  congenital anomalies that would predispose to sleep-disordered breathing (e.g.
             micrognathia)

          -  confirmed or suspected genetic syndromes that alter developmental outcomes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renee A Shellhaas, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Clinical Research Project Manager</last_name>
    <phone>734-232-8474</phone>
    <email>shatchew@med.umich.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shannon Clinical Subjects Coordinator</last_name>
    <phone>734-232-8473</phone>
    <email>shlester@med.umich.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anastasia Arynchyna</last_name>
      <email>Anastasia.Arynchyna@childrensal.org</email>
    </contact>
    <investigator>
      <last_name>Brandon Rocque, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Rau, BS, CCRP</last_name>
      <phone>734-232-8474</phone>
      <email>shatchew@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Renee A Shellhaas, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Ingram, PhD</last_name>
      <phone>612-813-6329</phone>
      <email>Katherine.Ingram@childrensmn.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Petronio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Haines</last_name>
      <email>Haines.Kelly@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Ellen Bendel-Stenzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Barton</last_name>
      <phone>314-747-1867</phone>
      <email>barton.anthony@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Jagruti Anadkat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jillian Jatres, MS</last_name>
      <phone>215-590-1505</phone>
      <email>JATRESJ@EMAIL.CHOP.EDU</email>
    </contact>
    <investigator>
      <last_name>Thorton A Mason, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly Diamond, BS, BA</last_name>
      <phone>412-692-9965</phone>
      <email>diamondkl@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Stephanie Greene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1038/s41372-019-0468-9</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Ren√©e Shellhaas, MD</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>polysomnogram</keyword>
  <keyword>development</keyword>
  <keyword>sleep apnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Meningomyelocele</mesh_term>
    <mesh_term>Spina Bifida Cystica</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

